Skip to main content
. 2014 Jul 28;12:234. doi: 10.1186/1477-7819-12-234

Figure 2.

Figure 2

Comparing progression-free survival (PFS) of the light chain multiple myelomapatients in the Velcade group and the group without Velcade (P= 0.036).